Tweets
@DrAshleyYip @RichardPAConway @drhectorchinoy @RheumNow EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.
Rohit Aggarwal @docrota ( View Tweet )
4 years 8 months ago
⭐️RA pts w/ high adipokines (fat-secreted proteins) have lower rates of LDA + remission independent of b/l dz activity & BMI
⭐️↑ adipokines esp adiponectin, then more likely to need b/tsDMARD
➡️Adipokines may be prognostic biomarkers 4 refractory dz.
Abst#0789 #ACR21 @RheumNow https://t.co/AFT22TzTFp
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
4 years 8 months ago
Marc Hochberg lecture at #ACR21 - Bisphosphonates limited and inconclusive data in radiographic progression of OA, some ⬇️ in bone marrow lesions!
@RheumNow https://t.co/ciMUINBLwm
Bella Mehta @bella_mehta ( View Tweet )
4 years 8 months ago
Abst 0981
Interesting study by Singer & colleagues examining economical and clinical burden of herpes zoster in patients with RA
- RA + HZ --> higher odds health resource utilization
- RA + HZ --> higher costs $$$
#ACR21 @RheumNow https://t.co/6Oc7ymbKHQ
Akhil Sood MD @AkhilSoodMD ( View Tweet )
4 years 8 months ago
TOFA Post hoc analysis on 2000pts:
⬆️ Paraoxonase PON1 activity associated w/
⬇ risk of malignancies (not NMSC) in RA pts treated w/ TOFA, Adj on RA duration, age, and smoking.
A promising biomarker! #Abst980 @RheumNow #ACR21 https://t.co/fOILnAyDN9
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 8 months ago
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression.
#Abs0909 #ACR21 @RheumNow
https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
Dr. Marc Hochberg delivering the Oscar Gluck Memorial lecture - His talk titled "The Role of Bone in OA". He begins with this statement.... "DJD... Should never be used" - the rest of the lecture explains why. #ACR21 https://t.co/lYGsFu4Wpr https://t.co/IWP5J73mFO
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran:
👉🏼>16000pts @ACRheum RISE
👉🏼Abatacept➡️larger decreases in CDAI in obese pts
👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts
@RheumNow #ACR21
https://t.co/bL5xnG1iNh
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
B cell repertoire: the new 🔮?
An algorithm associating baseline CDAI to BCR sequencing outcomes w/
✨Isotypes frequency
✨Somatic Hypermutations
predicts MTX 12mo response w/ 78% sens & spe
#Abstr982 #ACR21 @RheumNow
https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 8 months ago
Dusting off the old emergency supply right now (and there’s a lot of dust).
See? It said it on the side of the bottle all this time… they knew.
#ACR21 ABST0957 @RheumNow https://t.co/ygw6BkkjEp https://t.co/DqbIP8uL68
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Does #comorbidity burden affect treatment of #InflammatoryArthritis?
Abs#0577 #ACR21
👉🏼~6500pts; 11 types of IA
👉🏼Higher comorbidity burden➡️more likely to receive steroids than TNFis
👉🏼Are patients w/ IA & multiple comorbidities receiving suboptimal therapy?
@RheumNow #ACRBest https://t.co/iIERb0wL4Y
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
Stop by the RheumNow booth! #ACR21 #RheumPix https://t.co/e9dEwkfXU9
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
